Health Care • Biotechnology: Pharmaceutical Preparations
$0.77 ▼ -0.05
(-6.20%)
MKT CAP: $105.4M • VOL: 760.3K
52W L $1 52W H $7
ORGO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $564.2M | $482.0M | $433.1M |
| YoY Revenue Growth % | +17.0% | +11.3% | — |
| Gross Profit | — | $366.3M | — |
| Gross Margin % | — | 76.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $44.7M | -$1.3M | $12.5M |
| Operating Margin % | 7.9% | -0.3% | 2.9% |
| Net Income (GAAP) | $37.0M | $900.0K | $4.9M |
| EBITDA (Normalized) | $56.0M | $6.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.3M | $14.2M | $30.9M |
| Capital Expenditures (CapEx) | $14.2M | $10.0M | — |
| Free Cash Flow (FCF) | -$24.5M | $4.2M | $30.9M |
| FCF Margin % | -4.3% | 0.9% | 7.1% |
| Return on Invested Capital (ROIC %) | 17.1% | -0.8% | — |
| Cash & Short-Term Equivalents | $93.7M | $135.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $300.1M | $262.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ORGO.